(Q39011429)

English

Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway

scientific article published on 27 March 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

based on heuristic

inferred from title

author name string

X Li

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

H Miao

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Y Zhang

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

W Li

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Z Li

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Y Zhou

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

L Zhao

7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Q Guo

8

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

publication date

27 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Archives of Toxicology

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

89

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

121-136

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Targeting the tumor microenvironment: JAK-STAT3 signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Stat3 expression and its correlation with proliferation and apoptosis/autophagy in gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

The human ATP-binding cassette (ABC) transporter superfamily

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5).

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

The role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Targeting of CD44 eradicates human acute myeloid leukemic stem cells

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Bone marrow microenvironment in multiple myeloma progression.

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Novel agents in CML therapy: tyrosine kinase inhibitors and beyond

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Oroxylin A, a classical natural product, shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide.

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Tyrosine kinases as targets in cancer therapy - successes and failures

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-κB signaling pathway.

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinβ1 and its related pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest

1 reference

https://api.crossref.org/works/10.1007%2FS00204-014-1226-6

21 January 2018

Identifiers

10.1007/S00204-014-1226-6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39011429&oldid=2202458482"